European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019 - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles European Journal of Cancer Year : 2020

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019

1 Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen
2 PAFHCD - Portuguese Air Force Health Care Direction [Lisbon, Portugal]
3 Fondazione Policlinico Universitario Agostino Gemelli IRCCS
4 UKSH - University Medical Center of Schleswig–Holstein = Universitätsklinikum Schleswig-Holstein
5 UK - Univerzita Karlova [Praha, Česká republika] = Charles University [Prague, Czech Republic]
6 OUH - Odense University Hospital
7 King‘s College London
8 ULB - Université libre de Bruxelles
9 CIC Nantes - Centre d’Investigation Clinique de Nantes
10 CRCINA - Centre de Recherche en Cancérologie et Immunologie Nantes-Angers
11 UNIVAQ - University of L'Aquila [Italy]
12 AMU - Aix Marseille Université
13 APHM - Assistance Publique - Hôpitaux de Marseille
14 Medizinische Universität Wien = Medical University of Vienna
15 Frankfurt University Hospital
16 Aristotle University of Thessaloniki
17 HIPI (UMR_S_976 / U976) - Immunologie humaine, physiopathologie & immunothérapie
18 IDIBAPS - Institut d'Investigacions Biomèdiques August Pi i Sunyer
19 University of Oxford
20 Hospital Universitario Virgen Macarena [Séville]
21 University - Hospital of Modena and Reggio Emilia [Modena, Italy]
22 UVSQ - Université de Versailles Saint-Quentin-en-Yvelines
23 AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP)
24 University of Athens Medical School [Athens]
25 Universidade de Coimbra [Coimbra]
26 Università degli studi di Trieste = University of Trieste
27 Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico
28 Princess Máxima Center for Pediatric Oncology
Lars Bastholt
Aimilios Lallas
Mark Middleton
Ricardo Vieira

Abstract

Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumor and causes 90% of skin cancer mortality. A unique collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on CM diagnosis and treatment, based on systematic literature reviews and the experts' experience. The diagnosis of melanoma can be made clinically and shall always be confirmed through dermatoscopy. If a melanoma is suspected, a histopathological examination is required. Sequential digital dermatoscopy and full-body photography can be used in risk persons to detect the development of melanomas at an earlier stage. Where available, confocal reflectance microscopy can improve clinical diagnosis in special cases. Melanoma shall be classified according to the 8th version of the AJCC classification. Thin melanomas up to 0.8 mm tumor thickness does not require further imaging diagnostics. From stage IB onwards, examinations with lymph node sonography are recommended, but no further imaging examinations. From stage IIC whole-body examinations with CT or PET-CT in combination with brain MRI are recommended. From stage III and higher, mutation testing is recommended, particularly for BRAF V600 mutation. It is important to provide a structured follow-up to detect relapses and secondary primary melanomas as early as possible. There is no evidence to support the frequency and extent of examinations. A stage-based follow-up scheme is proposed, which, according to the experience of the guideline group, covers the minimum requirements; further studies may be considered. This guideline is valid until the end of 2021.
Embargoed file
Embargoed file
Visibility date is undetermined

Dates and versions

inserm-03677465 , version 1 (24-05-2022)

Identifiers

Cite

Claus Garbe, Teresa Amaral, Ketty Peris, Axel Hauschild, Petr Arenberger, et al.. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019. European Journal of Cancer, 2020, 126, pp.159 - 177. ⟨10.1016/j.ejca.2019.11.015⟩. ⟨inserm-03677465⟩
13 View
2 Download

Altmetric

Share

Gmail Facebook X LinkedIn More